Semax

A heptapeptide developed in Russia as a nootropic/stroke drug there — sold in the US as a nasal spray by creators and clinics.

⚠ Safety first — read this before anything else on this page

Approval status: Semax is not FDA-approved for any use in the United States. Its decades of prescription use in Russia are a fact about a foreign formulary, not a US safety finding. As of November 2026 it sits inside the draft federal enforcement-discretion policy — discretion is not approval.

What has actually happened to people:

No FDA-reviewed safety data exists for semax. In July 2026, FDA staff found the evidence insufficient to evaluate it. As an ACTH-fragment analog, stimulant-like and blood-pressure effects are the first questions a clinician would ask — and they are unstudied in any FDA-reviewed record (mechanism concern, not a documented event record).

What nobody knows: There are no US trials and no interaction data — including no data on use alongside the stimulant and psychiatric medications semax's nootropic audience commonly takes. That specific overlap is a flagged unknown, not a documented harm.

Get medical care now if:

Chest pain, a racing or pounding heartbeat, or a severe headache — seek urgent care and say what you took.
Agitation, anxiety, or sleeplessness that does not settle after stopping.
Swelling of the lips or tongue, or trouble breathing, after any use — call emergency services.

Who should stay away: Anyone with uncontrolled blood pressure or cardiovascular disease (the ACTH-analog mechanism question above), anyone taking stimulant or psychiatric medication (the interaction is untested), minors, and anyone pregnant.

The product problem: Across more than 7,000 gray-market samples of all compounds, independent tester Finnrick Analytics reports roughly one in three fail basic expectations — wrong identity, wrong quantity, or contamination (February 2026). Semax has no compound-specific testing dataset.

Talk to a doctor who knows you are taking it. See our doctors directory. If you were harmed, report it to FDA MedWatch — your report is how the record gets built.

We don't publish doses, protocols, or sources — for any compound, ever. Our Legal Mandate.

What it is

A heptapeptide developed in Russia as a nootropic/stroke drug there — sold in the US as a nasal spray by creators and clinics.

What creators claim

Creators present semax for focus and cognition; it anchors the Brain stack in creator taxonomies alongside selank and dihexa. Kim Constable (seller — labeled) covers semax/selank for ADHD-adjacent focus claims. Superpower lists a semax nasal spray in its preorder lineup.

What the evidence shows

Semax has a Russian clinical history (registered there for specific indications), but no FDA-reviewed human efficacy data and no US trials establishing benefit for cognition or any other use.

Forms it is discussed in

Nasal spray is the standard form discussed — the nose-to-brain route is the creators’ core claim, attributed as such.

Dangers on record

A stimulant-adjacent neuroactive compound with no US safety database; long-term data absent. See Dangers.

Legal status (as of November 7, 2026)

Not FDA-approved. PCAC voted 8–5 for the Bulks List (July 2026); not on the list. One of the six in the October 30 enforcement-discretion policy — specifically as the free base, single-ingredient, conditions apply.